oncology
Meet Pharma IQ’s advisory board: Nathalie Maubon
November 08 by Leila HawkinsPharma IQ’s advisory board member Nathalie Maubon on the future of drug testing
Natural killer cells: the next frontier for cancer treatment
July 11 by Leila HawkinsPharma IQ speaks to Cytovia Therapeutics about developing the next generation of cancer treatments
The latest in cancer treatments: Recreating the tumor environment
April 28 by Leila HawkinsPharma IQ speaks to HCS Pharma about creating the technology that reproduces tumor microenvironments to treat cancer
Sanofi announces partnership to develop new class of oncology therapeutics
March 30 by Leila HawkinsPharma IQ speaks to IGM Biosciences and Sanofi about their new collaboration
Too hard to handle? The challenges of handling and delivering highly potent oncology drugs
February 24 by Leila HawkinsLearn how to overcome the challenges of producing highly potent oncology drugs, from manufacture to distribution
How to maximize use of technology under master protocols for complex oncology studies
July 15 by Pharma IQExplore the underlying goal for using master protocols to increase the efficiency of your trial designs in 4G Clinical’s white paper
Repositive connects oncologists with cancer models
October 10 by Pharma IQ NewsRepositive launches limited-time free Personal Shopper Service, to connect researchers with difficult-to-source translational cancer models
Arix invests in oncology innovator VelosBio
October 01 by Pharmaceuticals & Biotechnology EditorUK health specialist Arix has led the investment in new ADC oncology treatment developed by next-generation oncology firm VelosBio.
Oncology treatments and immunotherapy
September 17 by George Clinical RepresentativeImmunotherapy and Checkpoint Inhibitors are Becoming a Paradigm in Treating Cancer, according to George Clinical.
Disclosure, finances, and the oncologist
September 11 by Pharmaceuticals & Biotechnology EditorDr José Baselga, CMO at the Memorial Sloan Kettering Cancer Centre, has neglected to fully disclose his vested interest in drug company sponsors.
Colorectal cancer screening now recommended five years earlier
August 06 by George Clinical RepresentativeColorectal cancer is the third-leading cause of American cancer deaths, and new research suggests screening should start five years earlier.
Epigenetics Market to climb to $16.3bn
October 30 by Chanice HenryA new research report from Grand View Research inc, charts that the international epigenetics market is due to reach US$16.31 billion by 2022. The forecasted growth being fuelled by the increasing f...